CÁNCER DE SENO: DE LA CIRUGÍA Y EL TAMOXIFEN A LA TERAPIA DIRIGIDA EN PACIENTES CON TUMORES HER2 POSITIVO Y LUMINALES

  • Hernán Carranza Instituto de Oncología, Colsánitas, Bogotá
Palabras clave: Cáncer de mama, tratamiento médico, terapia hormonal, receptor, terapia dirigida

Resumen

El cáncer de mama es la neoplasia más común entre las mujeres y representa un problema global para la salud pública. De acuerdo con estimaciones realizadas por la Organización Mundial de la Salud , en el año 2018 hubo a nivel mundial 2.1 millones casos nuevos y 627.000 muertes causadas por cáncer de mama. Historicamente el primer tratamiento considerado para cáncer de mama era quirúrgico. Si bien la estratificación histológica sigue siendo una práctica común, los avances tecnológicos han desentrañado más complejidades con la aparición de al menos cinco subtipos moleculares distintos. Sobre esta base, los análisis combinados genómico/transcriptómico de cánceres de mama han dado como resultado la identificación de diez subtipos distintos de cáncer de mama basados en grupos integrados. En línea con estos avances, también se han realizado esfuerzos para segregar aún más algunos de los subtipos histológicos establecidos para los cánceres de mama ER-negativos y triple negativos. En este artículo se presenta la evolución del manejo del cáncer de mama a la luz de los nuevos avances en el diagnóstico de la enfermedad.

Biografía del autor/a

Hernán Carranza, Instituto de Oncología, Colsánitas, Bogotá
Grupo Oncología Clínica y Traslacional, Instituto de Oncología, Colsánitas, Bogotá, Colombia. Investigador Asociado ONCOLGroup. Fundación para la Investigacion Clínica y Molecular Asociada al Cáncer FICMAC.

Citas

1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin.2018;68(6):394-424.
2. Ginsburg O, Bray F, Coleman M, Vanderpuye V, Eniu A, Kotha S et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847-860.
3. DANE [Internet]. Dane.gov.co. 2020 [consultado 18 Octubre 2020].Disponible en: http://www.dane.gov.co/files/investigaciones/poblacion/defunciones/defun-2005/CUADRO5.xls
4. Murillo R, Piñeros M, Hernández G. Atlas de mortalidad por cáncer en Colombia. Bogotá. Instituto Nacional de Cancerología, Instituto Geográfico Agustín Codazzi; Bogotá: INC, 2004.
5. Piñeros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia: an emerging problem. Cancer. 2004;101(10):2285-92.
6. Hernández G, Herrán S, Cantor LF. Análisis de las tendencias de mortalidad por cáncer de mama en Colombia y Bogotá, 1981 a 2000. Rev Colomb Cancerol. 2007;11(1):32-9.
7. Observatorio Nacional de Cáncer [Internet]. Minsalud. gov.co. 2020 [consultado 18 Octubre 2020]. Disponible en:
https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/guia-ross-cancer.pdf
8. Perou C, Sørlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
9. Curtis C, Shah S, Chin S, Turashvili G, Rueda O, Dunning M et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
10. Lehmann B, Jovanović B, Chen X, Estrada M, Johnson K, Shyr Y et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE. 2016;11(6):e0157368.
11. Crónica de la Medicina. Tomo I. 2º Edición. Edit. Plaza y Janés. Barcelona, 1995.
12. Halsted WS. The results of operation for the cure of cancer of the breast performed at John Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20(5):497- 555.
13. McGuire K, Santillan A, Kaur P, Meade T, Parbhoo J, Mathias M et al. Are Mastectomies on the Rise? A 13- Year Trend Analysis of the Selection of Mastectomy Vs. Breast Conservation Therapy in 5865 Patients. Ann Surg Oncol. 2009;16(10):2682-2690.
14. Fisher B, Jeong J, Anderson S, Bryant J, Fisher E, Wolmark N. Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation. N Engl J Med. 2002;347(8):567-575.
15. Fisher B, Anderson S, Bryant J, Margolese R, Deutsch M, Fisher E et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. N Engl J Med. 2002;347(16):1233-1241.
16. Diao K, Chen Y, Catalano P, Lee S, Milani N, Killoran J et al. Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. Radiother Oncol. 2017;125(2):301-309.
17. Gill G. Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Vs. Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Ann Surg Oncol. 2008;16(2):266-275.
18. Langer I, Guller U, Hsu-Schmitz S, Ladewig A, Viehl C, Moch H et al. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol. 2009;35(8):805-813.
19. Cancer Staging Manual. 8va ed. 2020.
20. Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B.Breast cancer intrinsic subtype classification, clinical use and future trends. Am J CancerRes. 2015;5(10):2929– 2943.
21. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
22. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001;12:S35-S41.
23. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
24. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D et al. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2– Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2006;24(18):2786-2792.
25. Valero V, Forbes J, Pegram M, Pienkowski T, Eiermann W, von Minckwitz G et al. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As FirstLine Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. J Clin Oncol. 2011;29(2):149-156.
26. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen A et al. Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study. J Clin Oncol. 2011;29(3):264-271.
27. Burstein H, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom P et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer. 2007;110(5):965-972.
28. Cortés J, Fumoleau P, Bianchi G, Petrella T, Gelmon K, Pivot X et al. Pertuzumab Monotherapy After TrastuzumabBased Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. J Clin Oncol. 2012;30(14):1594-1600.
29. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
30. Swain S, Baselga J, Kim S, Ro J, Semiglazov V, Campone M et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372(8):724-734.
31. Perez E, Barrios C, Eiermann W, Toi M, Im Y, Conte P et al. Trastuzumab Emtansine With or Without Pertuzumab Vs. Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol. 2017;35(2):141-148.
32. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F et al. Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/ Breast International Group 03-05 Study. J Clin Oncol. 2009;27(12):1999-2006.
33. Gelmon K, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol. 2012;30(15_suppl):LBA671-LBA671.
34. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
35. Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783- 1791.
36. Krop I, Kim S, Martin A, LoRusso P, Ferrero J, BadovinacCrnjevic T et al. Trastuzumab emtansine vs. treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743-754.
37. Rabindran S, Discafani C, Rosfjord E, Baxter M, Floyd M, Golas J et al. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. Cancer Res. 2004;64(11):3958-3965.
38. Burstein H, Sun Y, Dirix L, Jiang Z, Paridaens R, Tan A et al. Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. J Clin Oncol. 2010;28(8):1301-1307.
39. Awada A, Colomer R, Inoue K, Bondarenko I, Badwe R, Demetriou G et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. JAMA Oncology. 2016;2(12):1557.
40. Bang Y, Giaccone G, Im S, Oh D, Bauer T, Nordstrom J et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28(4):855-861.
41. Munster P, Krop I, LoRusso P, Ma C, Siegel B, Shields A et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119(9):1086-1093.
42. Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab vs. chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 2016;16:352
43. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G et al. Everolimus for women with trastuzumabresistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580-591.
44. Hurvitz S, Andre F, Jiang Z, Shao Z, Mano M, Neciosup S et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2- positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816-829.
45. Tolaney S, Burris H, Gartner E, Mayer I, Saura C, Maurer M et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014;149(1):151-161.
46. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. The Lancet. 2008;371(9606):29-40.
47. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber R, Forbes J et al. Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients—The International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007;25(3):263-270.
48. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Eur J Cancer. 2003;39(16):2318-2327.
49. Coombes R, Hall E, Gibson L, Paridaens R, Jassem J, Delozier T et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N Engl J Med. 2004;350(11):1081-1092.
50. Baselga J, Campone M, Piccart M, Burris H, Rugo H, Sahmoud T et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012;366(6):520-529.
51. Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936.
52. Im S, Lu Y, Bardia A, Harbeck N, Colleoni M, Franke F et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. NEngl J Med. 2019;381(4):307-316.
Publicado
2021-04-20
Sección
Perspectiva del diagnóstico y Tratamiento del Cancer